{"commentary":{"count":206,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":112,"youtube":50,"podcast":42,"x_video":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04351555\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NeoADAURA","nct_id":"NCT04351555","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=neoadaura-nct04351555. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"NeoADAURA","arms":[{"description":"Placebo plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)","label":"Arm 1: Placebo with platinum-based chemotherapy","type":"PLACEBO_COMPARATOR"},{"description":"Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator) plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)","label":"Arm 2: Osimertinib with platinum-based chemotherapy","type":"EXPERIMENTAL"},{"description":"Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator)","label":"Arm 3: Osimertinib monotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2029-06-13","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":358,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Osimertinib","type":"DRUG"},{"name":"Cisplatin","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Placebo","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"}],"last_update":"2026-09-09","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-10-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Major Pathological Response (MPR) - IASLC Method","timeFrame":"From date of randomization to an average of 12 weeks after the first dose"},{"measure":"Major Pathological Response (MPR) - Chemotherapy Method","timeFrame":"From date of randomization to an average of 12 weeks after the first dose"}],"references":[{"citation":"He J, Tsuboi M, Weder W, Chen KN, Hochmair MJ, Shih JY, Lee SY, Lee KY, Nhung NV, Saeteng S, Liu L, Xing L, Gia NH, Murakami S, Han Y, Saavedra MP, Yoon SH, Teixeira CHA, Escriu C, Martinez-Marti A, Blakely CM, Yatabe Y, Dacic S, Rukazenkov Y, Huang X, Dayal A, Chaft JE; NeoADAURA Investigators. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. J Clin Oncol. 2025 Sep 10;43(26):2875-2887. doi: 10.1200/JCO-25-00883. Epub 2025 Jun 2.","pmid":"40454705","type":"DERIVED"},{"citation":"Murat-Onana ML, Ramalingam SS, Janne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X. EGFR mutation testing across the osimertinib clinical program. Lung Cancer. 2025 Jun;204:108549. doi: 10.1016/j.lungcan.2025.108549. Epub 2025 Apr 18.","pmid":"40311309","type":"DERIVED"},{"citation":"Lee JB, Choi SJ, Shim HS, Park BJ, Lee CY, Sudhaman S, Velichko S, Hong MH, Cho BC, Lim SM. Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA). J Thorac Oncol. 2025 May;20(5):641-650. doi: 10.1016/j.jtho.2024.12.023. Epub 2024 Dec 26.","pmid":"39732365","type":"DERIVED"},{"citation":"Tsuboi M, Weder W, Escriu C, Blakely C, He J, Dacic S, Yatabe Y, Zeng L, Walding A, Chaft JE. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA. Future Oncol. 2021 Nov;17(31):4045-4055. doi: 10.2217/fon-2021-0549. Epub 2021 Jul 19.","pmid":"34278827","type":"DERIVED"}],"start_date":{"date":"2020-12-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT04351555"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/neoadaura-nct04351555"}